Xbrane Biopharma's revenues and losses increased

Biosimilar drug developer Xbrane Biopharma announced its financial results for the second quarter of 2026.

An increase was observed in the company's revenues and losses. This situation indicates an increasing cost or investment pressure in the firm's operations.